Indevus To Market Nebido In The U.S. Upon Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Indevus expects to file an NDA for the injectable testosterone therapy, licensed from Schering AG, for the treatment of hypogonadism in the second half of 2006.
You may also be interested in...
Endo Gets Surprise Aveed Approval, But REMS Could Be A Roadblock
After seven years of rejection, Endo finally gets FDA’s go-ahead on its long-acting testosterone treatment, but a strict REMS program and plenty of market competitors will make the drug’s launch difficult.
FDA Safety Concerns About Indevus’ Nebido Could Add 24 Months To Approval Timeline
Study to assess safety of hypogonadism therapy's oil-based depot injection could take 18 months.
FDA Safety Concerns About Indevus’ Nebido Could Add 24 Months To Approval Timeline
Study to assess safety of hypogonadism therapy's oil-based depot injection could take 18 months.